Read
- UK opposition party leader says Google tax behavior 'wrong'
- Microsoft unveils Xbox One with Spielberg, Activision tie-up
- White House threatens veto of bill to bypass Obama on Keystone
- Whole neighborhoods razed by Oklahoma tornado that killed 24
|
- Russia moves closer to jail terms for offending religion
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Devastated by tornado
A huge tornado tears through the Oklahoma City suburb of Moore, killing dozens. Slideshow
Nuclear tsunami wall
Safety upgrades designed to prevent a repeat of the Fukushima disaster. Slideshow
Sponsored Links
Gilead hepatitis C drug shows promise in late-stage trial
(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy.
The trial, named Positron, was testing the drug, sofosbuvir, in patients who were unable or unwilling to take interferon -- a standard hepatitis C drug known for its unpleasant side effects.
No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.
The safety profile of the drug was similar to that observed in prior studies, and there were few treatment discontinuations due to adverse events, Gilead said.
The company said it would submit the full data from the study for presentation at a scientific conference and will share data from additional late-stage studies in early 2013.
Gilead expects to submit its first regulatory filings for sofosbuvir by mid-2013, Chief Scientific Officer Norbert Bischofberger said.
(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters